Rituximab induction therapy in highly sensitized kidney transplant recipients

Chinese Medical Journal

Volumn 124, Issue 13, 2011, Pages 1928-1932

  Yin, Hang ^a   Wan, Hao ^a   Hu, Xiao Peng ^a   Li, Xiao Bei ^a   Wang, Wei ^a   Liu, Hang ^a   Ren, Liang ^a   Zhang, Xiao Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Highly sensitized; Kidney transplant; Rituximab

Indexed keywords

AMPHOTERICIN B; COMPLEMENT COMPONENT C4D; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; BLOOD GROUP TYPING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMODIALYSIS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LUNG ASPERGILLOSIS; LYMPHOCYTOTOXICITY; MALE; POSTOPERATIVE CARE; PREOPERATIVE CARE; RETROSPECTIVE STUDY; RISK REDUCTION; SINGLE DRUG DOSE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79960071634     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.13.002     Document Type: Article

References (23)

1. Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D, et al. Specific and durable elimination of antibody to donor HLA antigens in renaltransplant patients. Transplantation 2003; 76: 1519-1525.
2. Katzlneson S, Bhaduri S, Cecka JM. Clinical aspects of sensitization. Clin Transpl 1997; 285-296.
3. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262.
4. Montgomery RA, Cooper M, Kraus E, Rabb H, Samaniego M, Simpkins CE, et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transpl 2003; 199-213.
5. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79: 696-701.
6. Pescovitz MD, Book BK, Henson S, Leapman SB, Milgrom ML, Kimball J, et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with anti thymocyte globulin. Am J Transplant 2003; 3: 497-500.
7. Lederer SR, Friedrich N, Banas B, Welser G, Albert ED, Sitter T. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clin Transplant 2005; 19: 168-174.
8. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: whose problem is it? Front Biosci 2008; 13: 1396-1412.
9. Moore SB, Sterioff S, Pierides AM, Watts SK, Ruud CM. Transfusion-induced allo immunization in patients awaiting renal allografts. Vox Sang 1984; 47: 354-361.
10. Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005; 66: 334-342.
11. Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005; 44: 15150-15158.
12. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-174.
13. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
14. Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-661.
15. Pescovitz MD, Book BK, Henson S, Leapman SB, Milgrom ML, Kimball J, et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am J Transplant 2003; 3: 497-500.
16. Amante AJ, Ejercito R. Management of highly sensitized patients: Capitol Medical Center experience. Transplant Proc 2008; 40: 2274-2280.
17. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428.
18. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251.
19. Yin H, Hu XP, Li XB, Liu H, Wang W, Ren L, et al. Protein A immuno adsorption combined with rituximab in highly sensitized kidney transplant recipients. Chin Med J 2009; 122: 2752-2756.
20. Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET. Rituximab in highly sensitized kidney transplant recipients. Transplant Proc 2008; 40: 2218-2221.
21. Zhang XD, Hu XP, Yin H, Wang W, Zhang X, Ma LL, et al. Aspergillus pneumonia in renal transplant recipients. Chin Med J 2008; 121: 791-794.
22. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351.
23. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.